Molina R, Filella X, Mengual P, Prats M, Zanon G, Daniels M, Ballesta A M
Laboratory of Clinical Biochemistry (Unit for Cancer Research), School of Medicine, Hospital Clinico, Barcelona, Spain.
Int J Biol Markers. 1990 Jan-Mar;5(1):14-21.
MCA serum levels were determined in 27 healthy subjects, 136 with benign pathology (42 breast) and in 289 patients with cancer (247 active). The last group includes 223 patients with breast cancer (96 without metastases, 89 with metastases and 38 no-evidence of disease). CEA and CA15-3 serum levels were determined in all the patients with breast diseases. The mean levels of MCA were 4.7 + 2.4 U/ml in the control group, considering less than 11 U/ml as normal. MCA values were abnormal in 15.4% of patients with benign pathology, mainly in those with liver cirrhosis (8/20) and lung diseases (4/20). In the majority of these cases, the rise was only moderate, lower than 15 U/ml in 97.5% of patients. In malignant diseases, important increments were found in breast cancer (19.8% Mo, 77.5% M1) and ovarian cancer stages III-IV (44.4%). When we compared MCA serum levels with CA15-3 and CEA in breast pathology, a similar specificity was observed: 92.3%, 92.3% and 100% in cases with benign pathology and 92.1%, 94.7%, and 97.4% in NED patients, respectively. MCA and CA15-3 sensitivity was similar in breast cancer without metastases (19.8%) and lower for CEA (16.7%). In patients with breast cancer without metastases, we found a relation between positivity of these tumor markers and prognostic factors (tumor size, nodal involvement). The disease free interval in patients with locoregional breast cancer was shorter in cases with abnormal presurgical levels of some of the tumor markers, but only the difference from MCA was significant (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
在27名健康受试者、136名患有良性病变（42例为乳腺疾病）的患者以及289名癌症患者（247例为现患病例）中测定了MCA血清水平。最后一组包括223例乳腺癌患者（96例无转移、89例有转移以及38例疾病无证据者）。对所有乳腺疾病患者均测定了CEA和CA15-3血清水平。对照组MCA的平均水平为4.7 + 2.4 U/ml，将低于11 U/ml视为正常。15.4%的良性病变患者MCA值异常，主要见于肝硬化患者（8/20）和肺部疾病患者（4/20）。在大多数这些病例中，升高仅为中度，97.5%的患者低于15 U/ml。在恶性疾病中，乳腺癌（M0期19.8%，M1期77.5%）和卵巢癌III-IV期（44.4%）出现显著升高。当我们在乳腺病变中比较MCA血清水平与CA15-3和CEA时，观察到相似的特异性：良性病变病例分别为92.3%、92.3%和100%，疾病无证据患者分别为92.1%、94.7%和97.4%。在无转移的乳腺癌中，MCA和CA15-3的敏感性相似（19.8%），而CEA较低（16.7%）。在无转移的乳腺癌患者中，我们发现这些肿瘤标志物的阳性与预后因素（肿瘤大小、淋巴结受累情况）之间存在关联。局部区域性乳腺癌患者中，术前某些肿瘤标志物水平异常的患者无病生存期较短，但仅与MCA的差异具有显著性（p小于0.02）。（摘要截选至250词）
